Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q4 Earnings

by Sweta Killa

With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $68.25 in the latest trading session, marking a -0.44% move from the prior day.

Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

by Zacks Equity Research

Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

Tracey Ryniec headshot

Will Dividend Stocks be the Hot Stocks of 2019?

by Tracey Ryniec

With growth stocks sputtering to end 2018, investors seem poised to look in a new direction.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $68.52 in the latest trading session, marking a +1.89% move from the prior day.

NASH Space in Focus in 2019 as Firms Look to Diversify

by Zacks Equity Research

NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.

Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus

by Zacks Equity Research

It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $68.56 in the latest trading session, marking a +0.45% move from the prior day.

Gilead (GILD) Collaborates With Yuhan for NASH Candidates

by Zacks Equity Research

Gilead (GILD) collaborates with Korean company Yuhan for the development of NASH treatments.

Sweta Killa headshot

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Sweta Killa

Sector ETF report for PBE

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $61.88, marking a -1.68% move from the previous day.

Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018

by Zacks Equity Research

Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.

Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal

by Zacks Equity Research

It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.

Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III

by Zacks Equity Research

Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).

Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder

by Zacks Equity Research

Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.

Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija

by Zacks Equity Research

Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.

Immunomedics (IMMU) in Focus: Stock Moves 6.1% Higher

by Zacks Equity Research

Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead

by Zacks Equity Research

Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.

Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer

by Zacks Equity Research

Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.

Bristol-Myers to Sell French Consumer Health Unit for $1.6B

by Zacks Equity Research

Bristol-Myers (BMY) receives a $1.6 billion offer for its French consumer health unit from Japanese company, Taisho.

    Gilead Partners with Scholar Rock for Fibrotic Disease Drugs

    by Zacks Equity Research

    Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.

      Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint

      by Zacks Equity Research

      Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.

      Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod

      by Zacks Equity Research

      Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.

      Evofem Shares Up as Birth Control Gel Succeeds in Phase III

      by Zacks Equity Research

      Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birth control vaginal gel.

      Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer

      by Zacks Equity Research

      Puma Biotech (PBYI) reports positive top-line data from the phase III NALA study, conducted on its breast cancer drug Nerlynx in third-line setting.